The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
Physicians discuss the basics of NET diagnosis, classification, and progression. Particular attention is paid to the frequency of misdiagnosis. Two patients share their stories of delayed NET diagnosis and treatment due to the misidentification of symptoms.
FDA approves Gallium-68 DOTATOC PET/CT, another new imaging agent, for use in scanning neuroendocrine tumors. Data showed Gallium-68 DOTATOC superior to decades-old methods for disease staging, treatment planning, and identifying unknown primary sites.
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET
John Kanki, PhD, has joined Neuroendocrine Tumor Research Foundation (NETRF) as Director of Research. In this position, Dr. Kanki will oversee the strategic, scientific, and